Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL
Agency Denied Donanemab Accelerated Approval In January
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.
